Page last updated: 2024-08-22

camptothecin and Cancer of Pancreas

camptothecin has been researched along with Cancer of Pancreas in 377 studies

Research

Studies (377)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	20 (5.31)	18.2507
2000's	100 (26.53)	29.6817
2010's	228 (60.48)	24.3611
2020's	29 (7.69)	2.80

Authors

Authors	Studies
Kuang, Y; Ljungman, M; Neamati, N; Nurra, S; Sechi, M	1
Bazylevich, A; Bovina, A; Firer, MA; Gellerman, G; Hesin, A; Kostenich, G; Luboshits, G; Oron-Herman, M; Ragozin, E; Rubinek, T; Shekhter Zahavi, T; Sherman, MY; Tuchinsky, H; Wolf, I	1
Callan, B; Callan, JF; Gao, J; Griffith, DM; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M	1
Innocenti, F; Karas, S	1
Adam, R; Adenis, A; Aparicio, T; Assenat, E; Audemar, F; Bouché, O; Chauvenet, M; Fonck, M; Francois, E; Galais, MP; Ghiringhelli, F; Guimbaud, R; Houyau, P; Jouffroy, C; Khemissa, F; Kianmanesh, R; Lopez-Crapez, E; Mercier-Blas, A; Mineur, L; Rivoire, M; Thezenas, S; Ychou, M	1
Iga, N; Ishizaki, M; Kawai, H; Miyauchi, S; Mizuno, D; Nishi, H; Suemori, K; Uno, F; Yamashita, K; Yoshida, R	1
Bai, LY; Chan, DC; Chen, JS; Chen, LT; Chen, YY; Cheng, FM; Chiang, NJ; Chiu, SC; Chiu, TJ; Chou, WC; Chuang, SC; Hsueh, SW; Li, CP; Peng, CM; Shan, YS; Su, YY; Yang, SH; Yen, CJ	1
Li, Y; Padelford, J; Wang, L; Wu, AY; Xu, P; Xue, T; Xue, X	1
Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S	1
Balachander, A; Biswas, SK; Chen, S; Choo, SP; Chowbay, B; Guo, YA; Lam, J; Lee, B; Lee, SS; Leong, WF; Lim, TKH; Ng, M; Ong, WS; Seet, A; Skanderup, AJ; Sutiman, N; Tai, D; Yeong, J	1
Fukushima, T; Hamaguchi, T; Kobayashi, S; Morimoto, M; Nagashima, S; Oishi, R; Shin, M; Tezuka, S; Ueno, M; Yamachika, Y	1
Aihara, R; Araki, K; Hatanaka, T; Hosaka, H; Hoshino, T; Hosouchi, Y; Ijima, M; Ishida, F; Ishii, N; Kakizaki, S; Kobatake, T; Kurihara, E; Naganuma, A; Shirabe, K; Suzuki, Y; Tamura, Y; Uraoka, T; Yasuoka, H; Yoshida, S	1
Fu, W; Kai, GY; Li, L; Liu, XF; Liu, YQ; Peng, LZ; Xu, CR; Zhang, M; Zhang, ZJ; Zhu, LZ	1
Hamamoto, Y; Hazama, S; Iida, M; Ioka, T; Kanesada, K; Matsui, H; Nagano, H; Ogihara, H; Shindo, Y; Suzuki, N; Takeda, S; Tokumitsu, Y; Tsunedomi, R; Yoshida, S	1
Betrian, S; Brac De La Perriere, C; Chaltiel, L; Delord, JP; Sarradin, V	1
Furuse, J; Furuya, M; Ikeda, M; Ioka, T; Okusaka, T; Teng, Z; Ueno, M	1
Chen, BS; Cheng, TC; Chiang, CH; Chiu, JH; Hsieh, CL; Luan, YZ; Ma, KS; Peng, CM	1
Fushiki, K; Hamauchi, S; Kawakami, T; Onozawa, Y; Oshima, K; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T	1
Chen, C; Chen, J; Gong, M; Liang, X; Sun, S; Tang, Q; Wang, Y; Wu, R; Zhang, J	1
Duan, HQ; Duan, XC; Li, XZ; Liu, JT; Qin, N; Zhong, ZX	1
Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C	1
Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Kimura, M; Kotani, M; Nakabori, T; Nozaki, K; Ohkawa, K; Seiki, Y; Takada, R; Takagi, M; Uehara, H; Urabe, M; Watsuji, K; Yagi, T; Yamai, T	1
Arango, MJ; Noonan, AM; Porter, K; Reardon, J; Tossey, JC; VanDeusen, JB	1
Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V	1
Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N	1
Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y	1
Burrows, JF; Campbell, K; Chudasama, V; Greene, MK; Longley, DB; McDaid, WJ; Nogueira, JCF; Richards, DA; Scott, CJ; Tracey, SR	1
Ueno, M	1
Kasi, A; Paluri, RK; Posey, JA; Young, C	1
Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B	1
Borg, C; Chevalier, H; Edeline, J; El Hajbi, F; Hammel, P; Lièvre, A; Meurisse, A; Neuzillet, C; Peugniez, C; Turpin, A; Vernerey, D; Vienot, A	1
Foster, L; Lamarca, A; Satyadas, T; Siriwardena, A; Valle, JW	1
Al-Jumayli, M; Miller, K; Park, R; Saeed, A	1
Ayukawa, H; Endo, S; Furuse, J; Furuta, T; Hirano, R; Kaneko, S; Kawai, K; Kobayashi, T; Minowa, Y; Nagashima, F; Naruge, D; Okano, N; Shibasaki, H; Yokokawa, A	1
Ahn, S; Hwang, JH; Kim, HW; Kim, J; Kim, JW; Kim, YH; Lee, J; Lee, JC; Paik, KH	1
Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y	1
Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A	1
Lamb, YN; Scott, LJ	1
Azad, NS; De Jesus-Acosta, A; Donehower, RC; Fine, RL; Goggins, M; Jaffee, EM; Johnson, BA; Laheru, DA; Le, DT; Myzak, MC; Oberstein, PE; Yarchoan, M; Zheng, L	1
Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM	1
Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Shimamura, T; Tokuhisa, M	1
Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW	1
Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ	1
Barni, S; Ghidini, A; Inno, A; Labianca, R; Petrelli, F; Rimassa, L; Tomasello, G	1
Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z	1
Cinar, P; Ko, AH	1
Bai, XL; Chen, YG; Gao, SL; Guo, CX; Li, GG; Li, X; Liang, TB; Lou, JY; Ma, T; Que, RS; Shen, YN; Sun, PW; Wei, QC; Wei, SM; Yu, RS; Yuan, Y; Zhang, Q; Zhang, Y; Zheng, L	1
Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O	1
Liu, X; Lu, Z; Miao, Y; Shen, Y; Sui, M; Tang, J; Wang, L; Wang, W; Zheng, M; Zhou, Q; Zhou, Z	1
Liauw, SL	1
Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH	1
Bennouna, J; Bouché, O; Conroy, T; Desseigne, F; Gourgou, S; Jarlier, M; Juzyna, B; Robert, M; Ychou, M	1
Anbil, S; Baglo, Y; Fitzgerald, J; Hasan, T; Hayden, D; Huang, HC; Kalra, A; Lee, H; Liu, J; Paz, N; Pereira, S; Pogue, BW; Rizvi, I	1
Assenat, E; Bouarioua, N; Cadiot, G; Coriat, R; Dahan, L; Dubreuil, O; Elhajbi, F; Ferru, A; Gangloff, A; Granger, V; Hautefeuille, V; Hentic, O; Kurtz, JE; Le Malicot, K; Lepage, C; Lepere, C; Lievre, A; Lombard-Bohas, C; Malka, D; Roquin, G; Scoazec, JY; Smith, D; Walter, T	1
Arlt, A; Ceyhan, GO; Dantes, Z; Feuerecker, B; Hassan, Z; Knauer, SK; Krämer, OH; Rad, R; Reichert, M; Saur, D; Schmid, RM; Schneeweis, C; Schneider, G; Stauber, R; Veltkamp, C; Weichert, W; Wirth, M	1
Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T	1
Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K	1
Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH	1
Chevalier, H; Neuzillet, C; Turpin, A	1
Eskens, FALM; Groot Koerkamp, B; Nuyttens, JJ; Suker, M; van Eijck, CHJ	1
Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD	1
Ishigame, T; Kenjo, A; Kimura, T; Kofunato, Y; Marubashi, S; Muto, M; Okada, R; Sato, N; Shimura, T; Suzushino, S; Tsukida, S	1
Ahmad, E; Dai, Z; Gan, Y; Guo, S; He, S; Li, Y; Miao, Y; Shi, X; Song, W; Tian, F; Wang, R; Wu, Z; Yi, X; Yu, M; Zhang, X; Zhu, C	1
Bauernhofer, T; Hubmann, E; Jilek, K; Keil, F; Leitner, G; Pichler, A; Pichler, M; Rabl, H; Tinchon, C; Uggowitzer, M	1
Saif, MW	2
Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN	1
Kim, R; Kothari, N; Saif, MW	1
Saif, MW; Skoura, E; Syrigos, KN	1
Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U	1
Allen, JN; Blaszkowsky, LS; Clark, JW; Dias, LE; Faris, JE; Fernandez-del Castillo, C; Ferrone, CR; Guimaraes, AR; Hong, TS; Huynh, MA; Kwak, EL; Lillemoe, KD; McDermott, S; Murphy, JE; Ryan, DP; Sahani, DV; Szymonifka, J; Thayer, SP; Wargo, JA; Wo, JY; Zhu, AX	1
Gajdos, C; Jones, EL; Jones, TS; McManus, M; Shah, R	1
Bekaii-Saab, T; Goldberg, RM	1
Fu, Z; Wang, X; Yin, H; Zhang, X	1
Cooper, AB; Katz, MH; Tzeng, CW	1
Chen, LT; Dito, E; Ko, AH; Lin, YL; Ong, A; Shan, YS; Su, WC; Tempero, MA; Wang, YW; Yeh, CG	1
Chen, H; Deng, X; Jin, J; Li, H; Peng, C; Shen, B; Zhan, Q; Zhang, X	1
Carlomagno, C; Cella, CA; De Placido, S; De Stefano, A; Matano, E; Moretto, R; Raimondo, L	1
Bahary, N; Boone, BA; Gibson, MK; Krasinskas, AM; Lembersky, BC; Steve, J; Stoller, RG; Zeh, HJ; Zureikat, AH	1
Brunetti, AE; Nardulli, P; Russano, M; Silvestris, N	1
Dasanu, CA; Joseph, R	1
Brutcher, E; Chen, Z; El-Rayes, BF; Hawk, N; Kauh, J; Kim, S; Kooby, DA; Landry, J; Mahaseth, H; Maithel, SK	1
Brons, S; Combs, SE; Debus, J; Haberer, T; Schlaich, F; Weber, KJ	1
Asano, T; Ishii, M; Iwata, K; Kobayashi, H; Kobayashi, S; Koizumi, S; Okamura, R; Otsubo, T; Saji, O; Sumiyoshi, K	1
Bezan, A; Greil, R; Hauser-Kronberger, C; Hohla, F; Hopfinger, G; Rinnerthaler, G; Romeder, F; Stättner, S; Ulmer, H	1
Berger, AK; Jäger, D; Springfeld, C; Weber, TF	1
Dasanu, CA; Nandy, N	1
Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM	1
Chan, EH; Chan, SL; Chan, ST; He, ZX	1
Bitzer, M; König, C; Malek, NP; Plentz, RR; Schempf, U; Sipos, B	1
Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A	1
Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L	1
Oikonomopoulos, GM; Saif, MW; Skoura, E; Syrigos, KN	1
Jia, Y; Marks, E; Saif, MW	1
Benson, AB; Berlin, J; Burtness, B; Catalano, P; Chapman, AE; Liles, DK; Mitchell, E; Powell, M	1
Gillmore, R; Suarez Martinez-Falero, B	1
Blaszkowsky, LS; Cashavelly, BJ; Kim, CY; Penson, RT; Riley, JP; Ryan, DP; Schapira, L; Wold, MC	1
Kræmer, PC; Ladekarl, M; Schmidt, HH	1
Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY	1
Aoki, T; Fukayama, M; Hamada, T; Hasegawa, K; Isayama, H; Koike, K; Kokudo, N; Morikawa, T; Nakai, Y; Sakamoto, Y; Sasaki, T; Tanaka, M	1
Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I	1
Chang, BW; Johung, KL; Saif, MW	1
Papadatos-Pastos, D; Rabbie, R; Ross, P; Sarker, D; Thillai, K	1
Fung, KP; Lau, CB; Leung, PC; Leung, PS; Li, L; Yue, GG	1
Boucher, E; Boudjema, K; Hénno, S; Le Prisé, E; Levi Sandri, GB; Meunier, B; Sulpice, L; Turner, K	1
Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E	1
Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR	1
Chau, I; Cunningham, D; Khan, K; Moorcraft, SY; Peckitt, C; Rao, S; Watkins, D	1
Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A	1
Deng, Y; Li, J; Qin, S; Zhang, Z	1
Erickson, BA; Evans, DB; Ritch, PS	1
Allen, JN; Blaszkowsky, LS; Clark, JW; Deshpande, V; Faris, JE; Fernández-del Castillo, C; Ferrone, CR; Goyal, L; Hong, TS; Kwak, EL; Lillemoe, KD; Marchegiani, G; McDonnell, EI; Murphy, JE; Ryan, DP; Sabbatino, F; Santos, DD; Ting, DT; Warshaw, AL; Wo, JY; Zhu, AX	1
Dropkin, E; Strickler, JH; Strosberg, JR; Zhu, J	1
Uwagawa, T; Yanaga, K	1
Büchler, MW; Strobel, O	1
Herman, JM; Katz, MH; Marsh, Rde W; Talamonti, MS	1
Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H; Ueno, H	1
Addeo, P; Bachellier, P; Belletier, C; De Blasi, V; Dufour, P; Fuchshuber, P; Oussoultzoglou, E; Rosso, E; Simone, G	1
Shimizu, S	1
Aitini, E; Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Lonati, V; Petrelli, F	1
Duchêne, B; Jonckheere, N; Skrypek, N; Van Seuningen, I; Vasseur, R; Vincent, A	1
André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN	1
Arrojo, R; Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; Liu, D; Rossi, EA; Sharkey, RM; Trisal, P	1
Fusco, R; Granata, V; Izzo, F; Lastoria, S; Palaia, R; Petrillo, A; Piccirillo, M	1
Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A	1
Nipp, RD; Ryan, DP	1
Babel, I; Capello, M; Fleming, JB; Hanash, SM; Katz, MH; Lee, M; Maitra, A; Taguchi, A; Tian, W; Wang, H	1
Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S	1
El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH	1
Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; McBride, WJ; Rossi, EA; Sharkey, RM; Wang, Y	1
Barriuso, J; Borbath, I; Chougnet, CN; Crespo, G; Heetfeld, M; O'Toole, D; Olsen, IH; Pavel, M; Rinke, A; Walter, T	1
Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M	1
Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ	1
Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G	1
Coy, DH; Fuselier, JA; Mackey, LV; Qian, Q; Sun, G; Sun, L; Yu, CY	1
Jiang, JL; Liu, Y; Ma, T; Xi, WQ; Yang, C; Ye, ZB; Zhang, J; Zhou, CF; Zhu, ZG	1
Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK	1
Bachet, JB; Blanc, JF; Coriat, R; Cunha, AS; Hentic, O; Innominato, P; Laurent, C; Marthey, L; Pietrasz, D; Raoul, JL; Regenet, N; Taieb, J; Terrebonne, E; Trouilloud, I; Turrini, O; Wagner, M	1
Jabbar, AA; Zahir, MN	1
Braren, R; Erkan, M; Esposito, I; Friess, H; Holzapfel, K; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Schlitter, AM; Siveke, JT; Stöß, C; Wenzel, P	1
Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH	1
Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ	1
Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A	1
Akahori, T; Hirooka, S; Ikeda, N; Kinoshita, S; Kon, M; Kotsuka, M; Nagai, M; Nakajima, Y; Nishiwada, S; Ryota, H; Satoi, S; Sho, M; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H	1
Carnevale, J; Ko, AH	1
Chiang, CT; Ebrahim-Zadeh, N; Goldschmidt, R; Hasan, T; Huang, HC; Liu, J; Mai, Z; Mallidi, S; Rizvi, I	1
Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V	1
Itoi, T; Kamisawa, T; Takaori, K; Wood, LD	1
Chang, CH; Donahue, T; Kang, Y; Liao, Y; Liu, X; Meng, H; Nel, AE; Situ, A; Villabroza, KR	1
Byrne, JD; DeSimone, JM; Jajja, MR; Keeler, AW; Luft, JC; Schorzman, AN; Yeh, JJ; Zamboni, WC	1
Cherubini, G; Halldén, G; Lemoine, NR; Pantelidou, C	1
Ahn, DH; Bekaii-Saab, T; Bupathi, M; Ciombor, KK; Goldstein, DA; Reardon, J; Stephens, JA; Wu, C	1
Boustani, AM; Cha, CH; Chang, B; Cong, X; Deng, Y; Hochster, HS; Indukala, D; James, ES; Kortmansky, JS; Lacy, J; Li, J; Patel, V; Salem, RR; Staugaard, C; Stein, SM	1
Abe, Y; Agatsuma, T; Aida, T; Arakawa, S; Atsumi, R; Hagihara, K; Harada, N; Hayakawa, I; Hirai, T; Ishii, C; Nakada, T; Ogitani, Y; Oitate, M; Okamoto, H; Soma, M; Yamaguchi, J	1
Bai, X; Gao, S; Li, G; Liang, T; Lou, J; Ma, T; Que, R; Shen, S; Su, R; Wei, Q; Yu, R; Yuan, Y	1
Caparello, C; Catanese, S; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Vasile, E; Vivaldi, C	1
Lim, K; Ur Rehman, SS; Wang-Gillam, A	1
Belt, BA; Cusworth, BM; DeNardo, DG; Fields, RC; Fowler, KJ; Goedegebuure, SP; Hawkins, WG; Lim, KH; Linehan, DC; Lockhart, AC; Nieman, RK; Nywening, TM; Panni, RZ; Sanford, DE; Strasberg, SM; Suresh, R; Tan, BR; Toriola, AT; Wang-Gillam, A; Worley, LA; Yano, M	1
Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J	1
Cavaglione, G; Evesque, L; Follana, P; François, E; Gal, J; Reure, J; Saint, A	1
Ko, AH	2
Chang, JY; Chen, LT; Chiang, NJ; Shan, YS	1
Barile, R; Barone, C; Basso, M; Cassano, A; D'Argento, E; Martini, M; Rossi, S; Schinzari, G; Strippoli, A	1
Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A	1
Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN	1
Chiorean, EG; Coveler, AL; Herman, JM; Simeone, DM	1
Dai, B; Fleming, JB; Kang, Y; Li, X; Perez, MVR; Pratt, M; Roife, D	1
Ahmad, SA; Bekaii-Saab, T; Cardin, D; Collisson, E; Conway, W; Frankel, W; Herman, JM; Hoffman, JP; Katz, MH; Kindler, H; LoConte, N; Lowy, AM; Marsh, Rde W; Martin, R; Philip, P; Schwartz, L; Shen, P; Shi, Q; Talamonti, M; Truty, M; Venook, AP	1
Besselink, MG; Mohammad, NH; Molenaar, IQ; Rombouts, SJ; van Rijssen, LB; van Santvoort, HC; Vogel, JA; Walma, MS; Wilmink, JW	1
Ellenrieder, V; König, A; Seufferlein, T	1
Corvera, CU; Harris, HW; Hirose, R; Kim, GE; Kim, SS; Kirkwood, KS; Ko, AH; Nakakura, EK; Tempero, MA; Wang, ZJ	1
Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L	1
Brutcher, E; Cassidy, RJ; Chen, Z; El-Rayes, BF; Hawk, N; Kooby, D; Landry, J; Maithel, SK; Sarmiento, JM; Shaib, WL; Zhang, C	1
Bien, H; Choi, M; Mackenzie, GG	1
Caparello, C; Falcone, A; Funel, N; Garajova, I; Giovannetti, E; Kazemier, G; Le Large, TY; Meijer, LL; Peters, GJ; Vasile, E	1
Hsueh, CT; Selim, JH; Tsai, JY	1
Angele, MK; Boeck, S; Bruns, CJ; Burger, PJ; Haas, M; Hartwig, W; Heinemann, V; Kirchner, T; Kleespies, A; Kruger, S; Modest, DP; Ormanns, S; Werner, J; Westphalen, CB	1
Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y	1
Bohle, W; Egger, J; Hann, A; Zoller, WG	1
Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M	1
Astsaturov, I; Beglyarova, N; Bobrov, E; Cai, KQ; Campbell, K; Golemis, EA; Handorf, E; Khazak, V; Proia, DA; Restifo, D; Skobeleva, N	1
Gao, J; Gong, J; Li, J; Li, Y; Li, Z; Liu, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Yang, L; Zhang, X; Zhou, J	1
Carter, KA; Geng, J; Lovell, JF; Luo, D; Ortega, J; Razi, A; Shao, S	1
Antunes, C; Bachet, JB; Cassinotto, C; Lucidarme, O; Pietrasz, D; Sa Cunha, A; Wagner, M; Zappa, M	1
Belanger, B; Chen, LT; Hubner, R; Pipas, JM; Siveke, J; Von Hoff, D; Wang-Gillam, A	1
Gloor, B; Rau, T; Vinzens, S; Wochner, A; Zindel, J; Zweifel, M	1
Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR	1
Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A	1
Bodoky, G; Harsanyi, L; Hegyi, P; Lakatos, G; Nehéz, L; Petranyi, A; Szűcs, A	1
Eguchi, K; Furuse, J; Hamada, C; Iguchi, H; Ioka, T; Ishiguro, A; Ito, T; Itoi, T; Kida, M; Kitano, M; Komatsu, Y; Mizuno, N; Munakata, M; Ohkawa, S; Sakata, Y; Satoh, T; Takeda, K; Tanaka, M; Tsuji, A; Yamaguchi, T	1
Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J	1
Belk, KW; Kim, GP; Parisi, MF; Patel, MB; Pelletier, CL	1
Dawson, DW; Donahue, TR; Hines, OJ; Muthusamy, VR; Reber, HA; Sugimoto, M	1
Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A	1
Bernacki, RJ	1
Komatsu, Y; Munakata, M; Muto, O; Sakata, Y; Shimaya, S; Shitara, K; Yuki, S	1
Chang, MH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lee, JK; Lee, KT; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY	1
Gennatas, C; Gennatas, S; Michalaki, V	1
Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D	1
Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D	1
Cheng, CH; Lau, ST; Leung, PS; Liao, Y; Lin, ZX; Zhao, M	1
Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J	1
James, E; Saif, MW; Waldron-Lynch, MG	1
Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY	1
Shimizu, H; Yamaguchi, Y; Yoneda, E	1
Li, J; Saif, MW	1
Cardillo, TM; Goldenberg, DM; Govindan, SV; Hansen, HJ; Moon, SJ	1
Bechi, P; Cipriani, G; Grifoni, R; Molinara, E; Neri, B; Pantaleo, P; Pantalone, D; Rangan, S; Taddei, A; Tonelli, P; Valeri, A; Vannini, A	1
Han, DJ; Hwang, JY; Kim, JE; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, JS; Lee, SK; Lee, SS; Park, DH; Seo, DW; Yoo, C	1
Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA	1
Kaiho, T; Miyazaki, M; Nishimura, M; Nomura, S; Okamoto, R; Shinmura, K; Togawa, A; Tsuchiya, S; Yanagisawa, S	1
Koga, Y; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M	2
Choi, SH; Chun, HK; Lee, WS; Lee, WY	1
Carrie, C; de la Fouchardière, C; Desseigne, F; Labrosse, H; Martel Lafay, I; Méeus, P; Négrier, S; Pérol, D; Petit-Laurent, F; Rivoire, M; Tavan, D	1
Bae, I; Cho, CH; Hong, YB; Kallakury, BV; Kang, HJ; Kim, HJ; Kwon, KY; Kwon, SY; Lee, JM	1
Arcara, C; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E	1
Ali, S; Campbell-Baird, C; Harvey, H; Lipton, A; Witters, L	1
Mehta, SP	1
Antonijevic, MD; Forster, RE; Heaysman, CL; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Small, SA; Tang, Y	1
Araki, M; Hasegawa, H; Itoh, M; Kodama, Y; Kuzushita, N; Mano, M; Mita, E; Morita, K; Nakazuru, S; Ohta, M; Ohta, T; Suemura, S; Sueyoshi, Y; Toyama, T; Yoshio, T; Yoshioka, C	1
Kim, R	1
Kaley, K; Saif, MW	1
Coy, DH; Franko-Tobin, LG; Fuselier, JA; LePage, KT; Leslie, JS; Luo, J; Mackey, LV; Morris, LM; Sun, L	1
Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E	1
Li, FQ; Wang, W; Xie, XY; Yang, SW; Zhu, WP	1
Eilertsen, K; Jeansonne, DP; Kirk-Ballard, H; Koh, GY; Liu, D; Liu, Z; Wolff, L; Zhang, F	1
Kang, SP; Saif, MW	1
Makrilia, N; Saif, MW; Syrigos, KN	1
Alì, G; Bocci, G; Canu, B; Danesi, R; Del Tacca, M; Di Desidero, T; Di Paolo, A; Fioravanti, A; Fontanini, G; Orlandi, P	1
Goldenberg, DM; Govindan, SV; Karacay, H; Sharkey, RM	1
Buchsbaum, DJ; Fineberg, NS; Folks, KD; George, JF; Grizzle, WE; Guo, L; Kim, H; Morgan, DE; Sellers, JC; Stockard, CR; Zinn, KR	1
Park, JY	1
Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M	1
Li, Z; Lu, J; Tamanoi, F; Zink, JI	1
Chabot, J; Saif, MW	1
Abbruzzese, JL; Budillon, A; Carbone, C; Chiao, PJ; Ling, J; Melisi, D; Moccia, T; Paradiso, G; Xia, Q	1
Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M	1
Friess, H; Janssen, KP; Johannes, L; Keller, L; Kleeff, J; Langer, R; Maak, M; Nitsche, U; Rosenberg, R; Sarr, M; Thiebaud, M; Wolf, P	1
Lowery, MA; O'Reilly, EM	1
Burke, SJ; Campagna, SR; Collier, JJ; Eisenhauer, ME; Frydman, CJ; Lu, D; Sapp, RC	1
Bedenne, L; Bonnetain, F; Brixi-Benmansour, H; Cadiot, G; Hentic, O; Jouve, JL; Landi, B; Mitry, E	1
Milella, M; Sperduti, I; Vaccaro, V	1
Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M	1
Balivada, S; Basel, MT; Bossmann, SH; Pyle, MM; Seo, GM; Shrestha, TB; Tamura, M; Troyer, DL	1
Bowyer, C; Forster, RE; Lewis, AL; Lloyd, AW; Macfarlane, W; Phillips, GJ; Tang, Y	1
Jaeger, C; Kratz, F; Merfort, I; Naumann, K; Schmich, K	1
Fronza, M; Günther, S; Heinzmann, B; Lamy, E; Laufer, S; Merfort, I	1
Colucci, G; Di Maio, M; Giuliani, F; Perrone, F	1
Chen, LH; Leung, PS; Liang, J; Lin, ZX; Liu, L; Zhao, M	1
Fung, KP; Han, Q; Lau, CB; Leung, PC; Leung, PS; Li, L; Sun, H; Yue, GG	1
Aitini, E; Barni, S; Cascinu, S; Catalano, V; Codignola, C; Ferrara, D; Ferrari, D; Labianca, R; Valmadre, G; Veltri, E; Zaniboni, A	1
Itoh, T; Kawamoto, K; Takagi, K	1
Ernani, V; Hosein, PJ; Kawamura, C; Levi, JU; Loaiza-Bonilla, A; Macintyre, J; Maldonado, JC; Merchan, JR; Narayanan, G; Portelance, L; Ribeiro, A; Rocha-Lima, CM	1
Chargari, C; Deutsch, E; Huguet, F; Levy, A; Védrine, L	1
Couvelard, A; Gillet, A; Goujon, G; Hammel, P; Hentic, O; Lévy, P; Maire, F; Palazzo, M; Rebours, V; Ruszniewski, P; Zappa, M	1
Degenhardt, YY; Diskin, SJ; Haglund, E; Maris, JM; Mayes, PA; Moy, C; Toporovskya, Y; Wood, A; Wooster, R	1
Gao, F; Linehan, D; Lockhart, AC; Lubner, S; McWilliams, R; Menias, C; Peddi, PF; Picus, J; Sorscher, SM; Suresh, R; Tan, BR; Wang, J; Wang-Gillam, A	1
Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P	1
Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V	1
Basu, B; Jodrell, D	1
Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y	1
Manabe, S; Matsumura, Y; Tarin, D; Yasunaga, M	1
Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M	1
Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ	1
Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M	1
Hezel, AF; Katz, AW; Mondo, EL; Noel, MS; Schoeniger, LO	1
de la Fouchardière, C; Derbel, O; Méeus, P; Orlandini, F; Penet, AS; Pérol, M; Péron, J; Stella, M	1
Cong, X; Gunturu, KS; Hochster, HS; Lacy, J; Stein, SM; Thumar, JR; Yao, X	1
Conroy, T; Ducreux, M; Gavoille, C; Samalin, E; Ychou, M	1
Choi, EW; Cusack, JC; Donahue, JM; Fuchs, BC; Kasuya, H; Kawasaki, H; Kulu, Y; Kuruppu, DK; Tanabe, KK	1
Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA	1
Albertson, D; Blackstock, AW; Butler, JM; Howerton, R; Levine, E; Melin, SA; Patton, S; Pineau, B	1
Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M	1
Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P	1
Bearss, D; Von Hoff, DD	1
Needle, MN	1
André, T; Artru, P; Louvet, C	1
Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S	1
Heinemann, V	3
Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG	1
Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G	1
Haller, DG	2
Bouvet, M; Hoffman, RM; Katz, MH; Moossa, AR; Spivack, D; Takimoto, S	1
Haller, D; Sun, W	1
Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E	1
Pizzolato, JF; Saltz, LB	1
Kulke, MH	1
Hassan, AB; Markham, C; Stocken, DD	1
Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R	1
Cisar, LA; Green, MR; Gruia, G; Jeffrey, GM; Miller, LL; Miller, WH; Morganti, A; Orlando, N; Rocha Lima, CM; Rotche, R	1
Hada, M; Mizutari, K	1
Cantore, M; Del Freo, A; Fiorentini, G; Iacono, C; Mambrini, A; Manni, A; Oliani, C; Rabbi, C; Zamagni, D	1
Bonetto, E; Di Carlo, V; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A	1
Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX	1
Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L	1
Bugat, R; Conroy, T; Deplanque, G; François, E; Hua, A; Jacob, JH; Magherini, E; Metges, JP; Michel, P; Nasca, S; Paillot, B; Rixe, O; Stein, U	1
Burris, HA; Gerstein, H; Harris, J; Mettinger, KL; Reynolds, R; Rivkin, S; Staddon, A; Wax, A	1
Hoffman, RM	1
Berlin, J; Caillouette, C; Chakravarthy, B; Choy, H; Daniel Beauchamp, R; Lockhart, AC; Merchant, N; Rothenberg, M; Scott Pearson, A; Shyr, Y; Tedesco, KL; Wyman, K	1
Lopes, G; Rocha Lima, CM	1
Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G	1
Richards, DA	1
Berlin, JD	1
Ko, AH; Tempero, MA	1
Kato, T; Masuoka, HO; Sato, K; Tamahashi, N; Yano, H	1
Takimoto, CH	1
Clark, JW	1
Akaike, A; Matsukawa, M; Sato, A; Sekikawa, T; Ushio, J	1
Bartlett, DW; Cheng, J; Davis, ME; Heidel, JD; Hollister, B; Hwang, J; Schluep, T	1
Chua, YJ; Cunningham, D	1
Costanzo, C; Donadelli, M; Moore, PS; Palmieri, M; Piacentini, P; Scarpa, A	1
Ikeda, M; Morizane, C; Okusaka, T; Ueno, H	1
Baudin, E; Boige, V; de Baere, T; Dromain, C; Ducreux, MP; Duvillard, P; Elias, D; Kergoat, P; Lasser, P; Leboulleux, S; Malka, D; Sabourin, JC; Schlumberger, M	1
Funakoshi, A; Ishii, H; Ishikawa, O; Ohkawa, S; Okusaka, T; Saitoh, S; Ueno, H; Yamao, K	1
Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasada, T; Yamada, Y; Yamamitsu, S	1
Androulakis, N; Aravantinos, G; Boukovinas, J; Fountzilas, G; Georgoulias, V; Kotsakis, A; Papakotoulas, P; Polyzos, A; Potamianou, A; Samonis, G; Stathopoulos, GP; Syrigos, K; Varthalitis, J; Ziras, N	1
de Bruijn, P; de Jong, FA; Kitzen, JJ; Loos, WJ; Verweij, J	1
Abou-Alfa, GK; Ackerman, J; De Jager, RL; Eckhardt, SG; Feit, K; Harker, G; Hurwitz, H; Letourneau, R; Modiano, M; O'Reilly, EM; Tchekmedyian, NS	1
Owen, OG	1
Aoyagi, Y; Enomoto, T; Nakajima, M; Noguchi, M; Oda, T; Ohkohchi, N; Satake, M; Sugiura, S	1
Geng, M; Ji, YB; Jiang, JS; Li, H; Lou, GY; Ma, T; Xi, WQ; Xia, HQ; YeE, ZB	1
Aparicio, T; Artru, P; Asnacios, A; Desrame, J; Fallik, D; Landi, B; Lecomte, T; Lledo, G; Mansourbakht, T; Spano, JP; Taïeb, J	1
Fujioka, T; Hirashima, Y; Kitajima, K; Kumamoto, T; Murakami, K; Sugi, S	1
Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T	1
Beghelli, S; Dandrea, M; Di Carlo, V; Formicola, R; Mercalli, A; Piemonti, L; Reni, M; Scarpa, A; Sordi, V	1
Motoo, Y	1
Brix, G; Bruns, CJ; Dellian, M; Eichhorn, ME; Enders, G; Haas, H; Jauch, KW; Luedemann, S; Michaelis, U; Papyan, A; Ruhstorfer, H; Sauer, B; Strieth, S; Teifel, M	1
Aoki, M; Ishiguro, A; Itoh, J; Munakata, A; Munakata, M; Sakata, Y; Shitara, K; Suzuki, K; Takahata, T	1
Buchsbaum, DJ; DeRosier, LC; Grizzle, WE; Huang, ZQ; Long, JW; Oliver, PG; Sellers, JC; Vickers, SM; Wang, W; Zhou, T; Zinn, KR	1
Haller, DG; Hershock, D; Hewitt, MR; Sun, W; Theobald, MR	1
Meric, JB	1
Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP	1
Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M	1
Greenberger, LM; Horak, ID; Kraft, P; Longley, C; Malaby, J; Mehlig, M; Sapra, P; Zhao, H	1
Balsari, A; Carenini, N; De Cesare, M; Perego, P; Petrangolini, G; Pratesi, G; Tortoreto, M; Zunino, F	1
Buitenhuis, M; Catimel, G; Dirix, LY; Mathieu-Boué, A; Siegenthaler, P; Verdonk, HE; Verweij, J; Wagener, DJ	1
Geoffroy, F; Grem, JL	1
Kamataki, T; Sakata, Y; Suzuki, H	1
Futatsuki, K; Kambe, M; Nakao, I; Ogawa, N; Sakata, Y; Shimada, Y; Taguchi, T; Wakui, A; Yoshino, M	1
Beijnen, J; de Boer-Dennert, M; Hansen, H; Koier, I; Lund, B; Planting, A; Rosing, H; Verweij, J	1
Dalgleish, AG; Gibson, FM; Gordon-Smith, EC; Marsh, JC; Philpott, NJ; Scopes, J; Turner, AJ; Westby, M	1
Alexander, R; Amfoh, K; Engstrom, PF; Fox, S; Green, F; Kosierowski, R; Lusch, C; O'Dwyer, PJ; Raskay, B; Redei, I; Scher, RM	1
Donehower, RC; Grochow, LB; O'Reilly, S; Ord, S; Rowinsky, EK	1
Sakata, Y; Suzuki, H; Takemori, H	1
Armand, JP; Couteau, C; Terret, C	1
Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A	1
Rosen, LS	1
Kobayashi, A; Yamaguchi, M	1
Coil, D; Davis, B; De Ipolyi, PD; Giovanella, BC; Natelson, EA; Stehlin, JS; Trojacek, A; Wallace, P; Wolk, D	1
Stucky-Marshall, L	1
Bleiberg, H	1
Bruns, CJ; Davis, DW; Dong, Z; Fidler, IJ; Harbison, MT; Killion, JJ; McConkey, DJ; Nelkin, G; Shinohara, H	1
Kitagata, S; Mai, M; Takahashi, Y	1
Giovanella, B; Kemp, KR; Liehr, JG	1
Bahadori, H; Brescia, FJ; Green, MR; Harper, M; Mushtaq, CM; Rocha Lima, CM; Safa, A; Sherman, CA	1
Brescia, FJ; Brunson, CY; Green, MR; Rocha Lima, CM; Sherman, CA	1
Bruckner, HW; Evans, A; Kozuch, P; Petryk, M	1
Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ	1
Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A	1
Antonakis, PT; Golematis, BX; Konstadoulakis, MM; Manouras, AP; Mylonaki, DB; Stathopoulos, GP; Tsibloulis, BG	1
Bruckner, H; Compton, LD; Dudek, A; Eckardt, J; Elfring, GL; Green, MR; Hainsworth, J; Lester, E; Locker, PK; Miller, LL; Miller, W; Rocha Lima, CM; Savarese, D; Saville, W; Yunus, F	1
Blumenthal, RD; Goldenberg, DM; Leon, E; Reising, A	1
Agrawal, S; Ball, R; Chen, SF; Dexter, DL; Hollister, BA; Kandimalla, ER; Lombardi, G; Lucas, T; Yu, D	1
Bruckner, HW; Kozuch, P; Petryk, M	1
Kono, A; Sato, K; Shimazoe, T; Sugimoto, Y; Takeda, S; Tsuruo, T	1
Kono, A; Kuga, H; Sato, K; Shimazoe, T; Takeda, S	1
Hara, Y; Kono, A	1
Kono, A; Takeda, S	1

Reviews

67 review(s) available for camptothecin and Cancer of Pancreas

Article	Year
Second-line treatment for metastatic pancreatic cancer. Clinical advances in hematology & oncology : H&O, 2020, Volume: 18, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms	2020
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma. Drugs, 2017, Volume: 77, Issue:7 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2017
Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. European journal of cancer (Oxford, England : 1990), 2017, Volume: 81 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy	2017
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017. Chinese clinical oncology, 2017, Volume: 6, Issue:3 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Gentamicins; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Practice Guidelines as Topic; Treatment Outcome; United States	2017
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis. Journal of cellular physiology, 2018, Volume: 233, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2018
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review . Clinical nephrology, 2018, Volume: 90, Issue:2 Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids	2018
Locally advanced pancreatic cancer. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic	2013
First-line treatment for advanced pancreatic cancer. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic	2013
Second-line therapy in pancreatic cancer. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur	2013
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update. Chinese journal of cancer, 2014, Volume: 33, Issue:6 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor	2014
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. Expert review of anticancer therapy, 2014, Volume: 14, Issue:10 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2014
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer. Surgery today, 2015, Volume: 45, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome	2015
Pancreatic cancer and FOLFIRINOX: a new era and new questions. Cancer medicine, 2015, Volume: 4, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Care Planning; Postoperative Care; Preoperative Care; Randomized Controlled Trials as Topic; Treatment Outcome	2015
Chemotherapy for advanced poorly differentiated pancreatic neuroendocrine carcinoma. Journal of hepato-biliary-pancreatic sciences, 2015, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Administration Schedule; Etoposide; Everolimus; Humans; Irinotecan; Pancreatic Neoplasms	2015
FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies. Pancreas, 2015, Volume: 44, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome	2015
MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future oncology (London, England), 2016, Volume: 12, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Drug Combinations; Drug Discovery; Drug Evaluation, Preclinical; Humans; Neoplasm Staging; Pancreatic Neoplasms; Sucrose; Treatment Outcome	2016
Pancreatic cancer. Lancet (London, England), 2016, Jul-02, Volume: 388, Issue:10039 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53	2016
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer. Expert review of anticancer therapy, 2016, Volume: 16, Issue:5 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Nanoparticles; Pancreatic Neoplasms; Randomized Controlled Trials as Topic	2016
Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan. International journal of nanomedicine, 2016, Volume: 11 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Liposomes; Nanomedicine; Nanotechnology; Pancreatic Neoplasms	2016
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:10 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Combinations; Fluorouracil; Humans; Leucovorin; Pancreatic Neoplasms; Sucrose; Treatment Outcome	2016
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. The Lancet. Oncology, 2016, Volume: 17, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate	2016
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy. Expert review of anticancer therapy, 2016, Volume: 16, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Prognosis	2016
Localized Pancreatic Cancer: Multidisciplinary Management. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2016, Volume: 35 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Radiosurgery	2016
Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer. Annals of surgical oncology, 2016, Volume: 23, Issue:13 Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Radiotherapy, Adjuvant; Survival Rate	2016
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma. Digestion, 2016, Volume: 94, Issue:1 Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms	2016
Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer. Recent patents on anti-cancer drug discovery, 2016, Volume: 11, Issue:4 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Drug Compounding; Drug Resistance, Neoplasm; Humans; Irinotecan; Liposomes; Pancreatic Neoplasms; Patents as Topic; Treatment Outcome	2016
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World journal of gastroenterology, 2016, Aug-21, Volume: 22, Issue:31 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Precision Medicine; Translational Research, Biomedical; Vascular Endothelial Growth Factor A	2016
Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma. World journal of gastroenterology, 2016, Aug-21, Volume: 22, Issue:31 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; CA-19-9 Antigen; Camptothecin; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Nanoparticles; Paclitaxel; Pancreatic Neoplasms	2016
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. Cancer treatment reviews, 2016, Volume: 50 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic	2016
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World journal of gastroenterology, 2016, Dec-14, Volume: 22, Issue:46 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome	2016
The role of capecitabine in the management of tumors of the digestive system. Reviews on recent clinical trials, 2009, Volume: 4, Issue:1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A	2009
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anti-cancer drugs, 2009, Volume: 20, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Genes, BRCA2; Genetic Predisposition to Disease; Humans; Irinotecan; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate	2009
Palliative chemotherapy for pancreatic malignancies. The Surgical clinics of North America, 2010, Volume: 90, Issue:2 Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus	2010
[Second line chemotherapy for pancreatic cancer]. The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2011, Volume: 57, Issue:4 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids	2011
FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity. Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2013
The role of the FOLFIRINOX regimen for advanced pancreatic cancer. Current oncology reports, 2013, Volume: 15, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2013
New drugs for patients with pancreatic cancer. Current opinion in oncology, 2002, Volume: 14, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Capecitabine; Deoxycytidine; Diphtheria Toxoid; Fluorouracil; Gastrins; History, 16th Century; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic	2002
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody. Seminars in oncology, 2002, Volume: 29, Issue:5 Suppl 14 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms	2002
[Gemcitabine-based combinations in inoperable pancreatic cancers]. Bulletin du cancer, 2002, Volume: 89 Spec No Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome	2002
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 20 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids	2002
Chemotherapy for advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2003, Volume: 56, Issue:4 Suppl Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome	2003
New perspectives in the management of pancreas cancer. Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 11 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids	2003
[The update on pancreatic cancer chemotherapy]. Medicina (Kaunas, Lithuania), 2003, Volume: 39, Issue:10 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors	2003
Irinotecan (Campto) in the treatment of pancreatic cancer. Expert review of anticancer therapy, 2003, Volume: 3, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Irinotecan; Pancreatic Neoplasms	2003
Advanced pancreatic cancer: is there a role for combination therapy? Expert review of anticancer therapy, 2003, Volume: 3, Issue:5 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine Endopeptidases; Deoxycytidine; Fluorouracil; Gemcitabine; Genes, ras; Glutamates; Guanine; Humans; Multienzyme Complexes; Pancreatic Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Sesquiterpenes	2003
Docetaxel in the management of advanced pancreatic cancer. Seminars in oncology, 2005, Volume: 32, Issue:2 Suppl 4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide	2005
Chemotherapeutic gemcitabine doublets in pancreatic carcinoma. Seminars in oncology, 2005, Volume: 32, Issue:4 Suppl 6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate	2005
Systemic therapy for pancreatic cancer. Seminars in radiation oncology, 2005, Volume: 15, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines	2005
Rubitecan. Expert opinion on investigational drugs, 2006, Volume: 15, Issue:1 Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Evaluation, Preclinical; Enzyme Inhibitors; Female; Humans; Male; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors	2006
[Irinotecan chemotherapy for patients with advanced or relapsed pancreatic neoplasm]. Nihon rinsho. Japanese journal of clinical medicine, 2006, Volume: 64 Suppl 1 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasm Recurrence, Local; Pancreatic Neoplasms	2006
Chemotherapy for advanced pancreatic cancer. Best practice & research. Clinical gastroenterology, 2006, Volume: 20, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors	2006
[Non-surgical treatment for pancreatic cancer]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2006, Volume: 103, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Tegafur	2006
[Diagnosis of and therapy for pancreatic neoplasms]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2007, Apr-10, Volume: 96, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Diabetes Complications; Drug Combinations; Early Diagnosis; Gemcitabine; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tegafur	2007
[Angiogenesis targeting in gastro-intestinal cancers]. Bulletin du cancer, 2007, Volume: 94, Issue:7 Suppl Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms	2007
Chemotherapy of advanced gastrointestinal cancer. Current opinion in oncology, 1994, Volume: 6, Issue:4 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Combined Modality Therapy; Digestive System Neoplasms; Double-Blind Method; Drugs, Investigational; Gastrointestinal Neoplasms; Humans; Immunologic Factors; Infusions, Intra-Arterial; Irinotecan; Leucovorin; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome	1994
[Chemotherapy for pancreatic cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids	1996
CPT-11: the European clinical development. The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Female; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms	1996
Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Williston Park, N.Y.), 1998, Volume: 12, Issue:8 Suppl 6 Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Humans; Irinotecan; Leukemia; Lung Neoplasms; Lymphoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms	1998
New agents in gastrointestinal malignancies: Part 1: Irinotecan in clinical practice. Cancer nursing, 1999, Volume: 22, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Humans; Irinotecan; Neoplasm Metastasis; Oncology Nursing; Pancreatic Neoplasms	1999
CPT-11 in gastrointestinal cancer. European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Pancreatic Neoplasms; Stomach Neoplasms	1999
Gemcitabine: progress in the treatment of pancreatic cancer. Oncology, 2001, Volume: 60, Issue:1 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome	2001
Irinotecan in the management of patients with pancreatic cancer. Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:12 Suppl 1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Humans; Irinotecan; Multicenter Studies as Topic; Pancreatic Neoplasms	2000
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer. Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:3 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms	2001
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review. The Surgical clinics of North America, 2001, Volume: 81, Issue:3 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Methotrexate; Pancreatic Neoplasms; Randomized Controlled Trials as Topic	2001
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies. Seminars in oncology, 2001, Volume: 28, Issue:3 Suppl 10 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms	2001
Gemcitabine-based combination treatment of pancreatic cancer. Seminars in oncology, 2002, Volume: 29, Issue:1 Suppl 3 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome	2002
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome	2002

Trials

83 trial(s) available for camptothecin and Cancer of Pancreas

Article	Year
Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. British journal of cancer, 2022, Volume: 126, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms	2022
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects. International journal of cancer, 2022, 08-01, Volume: 151, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorouracil; Humans; Immunity; Irinotecan; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2022
Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial. Japanese journal of clinical oncology, 2023, Jan-28, Volume: 53, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; East Asian People; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms	2023
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. American journal of clinical oncology, 2019, Volume: 42, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Membrane Proteins; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Radiosurgery; Risk Assessment; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome	2019
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR European journal of cancer (Oxford, England : 1990), 2020, Volume: 136 Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome	2020
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. British journal of cancer, 2017, May-09, Volume: 116, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate	2017
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure. Medicine, 2017, Volume: 96, Issue:19 Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retreatment; Treatment Outcome	2017
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). British journal of cancer, 2017, Jun-27, Volume: 117, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting	2017
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4). Oncology, 2017, Volume: 93, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Retrospective Studies	2017
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2018, Volume: 50, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Neuroendocrine; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Intestinal Neoplasms; Leucovorin; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Research Design; Stomach Neoplasms; Survival Analysis; Treatment Outcome	2018
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy. Anticancer research, 2018, Volume: 38, Issue:4 Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur	2018
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. Annals of surgical oncology, 2018, Volume: 25, Issue:7 Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate	2018
Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2013
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. British journal of cancer, 2013, Aug-20, Volume: 109, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Liposomes; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Sucrose; Treatment Outcome	2013
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:11 Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptothecin; Dexamethasone; Drug Combinations; Female; Fluorouracil; Haloperidol; Humans; Leucovorin; Male; Metoclopramide; Morpholines; Nausea; Organoplatinum Compounds; Pancreatic Neoplasms; Vomiting	2013
Randomized Phase II Trial of Irinotecan/Docetaxel or Irinotecan/Docetaxel Plus Cetuximab for Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study. American journal of clinical oncology, 2016, Volume: 39, Issue:4 Topics: Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cetuximab; Diarrhea; Disease-Free Survival; Docetaxel; Enoxaparin; Female; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Response Evaluation Criteria in Solid Tumors; Survival Rate; Taxoids; Thromboembolism	2016
MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer. JOP : Journal of the pancreas, 2014, May-27, Volume: 15, Issue:3 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Sucrose	2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:18 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome	2014
Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results. International journal of surgery (London, England), 2015, Volume: 18 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Deoxycytidine; Electrochemotherapy; Female; Fluorouracil; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Young Adult	2015
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients. Oncotarget, 2015, Sep-15, Volume: 6, Issue:27 Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics	2015
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas, 2016, Volume: 45, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting	2016
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet (London, England), 2016, Feb-06, Volume: 387, Issue:10018 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting	2016
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome	2016
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience. Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Costs and Cost Analysis; Disease-Free Survival; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome	2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer. British journal of cancer, 2016, Mar-29, Volume: 114, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate	2016
Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. The Lancet. Oncology, 2016, Volume: 17, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Macrophages; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Pyrrolidines; Receptors, CCR2	2016
Preoperative Modified FOLFIRINOX Treatment Followed by Capecitabine-Based Chemoradiation for Borderline Resectable Pancreatic Cancer: Alliance for Clinical Trials in Oncology Trial A021101. JAMA surgery, 2016, 08-17, Volume: 151, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate	2016
A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458). International journal of radiation oncology, biology, physics, 2016, 10-01, Volume: 96, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome	2016
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome	2016
Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study. Oncotarget, 2017, Apr-11, Volume: 8, Issue:15 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cisplatin; Female; Humans; Induction Chemotherapy; Intestinal Neoplasms; Irinotecan; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome	2017
Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. Pathology oncology research : POR, 2017, Volume: 23, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2017
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. British journal of cancer, 2017, Feb-14, Volume: 116, Issue:4 Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome	2017
Pilot study of combination chemotherapy using irinotecan plus S-1 for metastatic pancreatic cancer. Oncology, 2008, Volume: 75, Issue:1-2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Tegafur; Treatment Outcome	2008
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms	2009
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Digestive System Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome; Vitamin B Complex	2010
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors. Cancer investigation, 2009, Volume: 27, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome	2009
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Investigational new drugs, 2010, Volume: 28, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Pilot Projects; Salvage Therapy; Survival Analysis	2010
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer. Oncology research, 2009, Volume: 17, Issue:11-12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms	2009
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. British journal of cancer, 2009, Nov-17, Volume: 101, Issue:10 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome	2009
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United States	2009
Phase I study of daily irinotecan as a radiation sensitizer for locally advanced pancreatic cancer. International journal of radiation oncology, biology, physics, 2010, Jun-01, Volume: 77, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Camptothecin; Disease Progression; Drug Administration Schedule; Feasibility Studies; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Survival Analysis	2010
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer. Journal of clinical gastroenterology, 2010, Volume: 44, Issue:4 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Celecoxib; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Pyrazoles; Sulfonamides; Treatment Outcome	2010
FOLFIRINOX: a new standard treatment for advanced pancreatic cancer? The Lancet. Oncology, 2011, Volume: 12, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis	2011
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2011, Volume: 43, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Disease-Free Survival; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Pancreatic Neoplasms; Treatment Outcome	2011
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate	2012
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. JOP : Journal of the pancreas, 2012, Sep-10, Volume: 13, Issue:5 Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2012
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome	2013
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2013
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate	2013
Irinotecan and gemcitabine in patients with solid tumors: phase I trial. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting	2002
Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer. Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Irinotecan; Neutropenia; Pancreatic Neoplasms	2002
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients. Journal of cancer research and clinical oncology, 2002, Volume: 128, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms	2002
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:3 Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome	2003
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. British journal of cancer, 2003, Apr-22, Volume: 88, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome	2003
Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study. Oncology (Williston Park, N.Y.), 2003, Volume: 17, Issue:9 Suppl 8 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Pancreatic Neoplasms; Research Design	2003
A phase II irinotecan-cisplatin combination in advanced pancreatic cancer. British journal of cancer, 2003, Nov-17, Volume: 89, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome	2003
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors. Anti-cancer drugs, 2004, Volume: 15, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms	2004
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Sep-15, Volume: 22, Issue:18 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis	2004
Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology, 2004, Volume: 67, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2004
Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer investigation, 2004, Volume: 22, Issue:5 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Pancreatic Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome	2004
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer. Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome	2004
Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Feb-20, Volume: 23, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Analysis	2005
Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. The oncologist, 2005, Volume: 10, Issue:3 Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Camptothecin; Disease Progression; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis	2005
A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2005, Volume: 76, Issue:1 Topics: Adenocarcinoma; Administration, Oral; Aged; Camptothecin; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage	2005
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer. American journal of clinical oncology, 2005, Volume: 28, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting	2005
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with pretreated gastroenteropancreatic well-differentiated endocrine carcinomas. Oncology, 2006, Volume: 70, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Drug Administration Schedule; Enteroendocrine Cells; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure; Treatment Outcome	2006
A phase II study of weekly irinotecan as first-line therapy for patients with metastatic pancreatic cancer. Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:4 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms	2007
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British journal of cancer, 2006, Sep-04, Volume: 95, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Compliance	2006
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Sep-20, Volume: 24, Issue:27 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome	2006
FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Paris; Prospective Studies; Time Factors; Treatment Outcome	2007
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anti-cancer drugs, 2007, Volume: 18, Issue:3 Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome	2007
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Cancer, 2007, Dec-15, Volume: 110, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate	2007
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study. Cancer investigation, 2008, Volume: 26, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Taxoids	2008
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study. Oncology, 2007, Volume: 72, Issue:5-6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis	2007
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bone Marrow Diseases; Camptothecin; Disease-Free Survival; Female; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Treatment Outcome	1995
[A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:7 Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms	1994
Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:8 Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Camptothecin; Female; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Remission Induction; Topoisomerase I Inhibitors; Topotecan	1993
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Investigational new drugs, 1996, Volume: 13, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Topotecan	1996
A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anti-cancer drugs, 1996, Volume: 7, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Topotecan	1996
A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. International journal of oncology, 1999, Volume: 14, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Patient Selection; Quality of Life; Survival Analysis; Tomography, X-Ray Computed	1999
A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma. Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Female; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies	2001
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Mar-01, Volume: 20, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Safety; Survival Rate; Treatment Outcome	2002

Other Studies

227 other study(ies) available for camptothecin and Cancer of Pancreas

Article	Year
Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. Journal of medicinal chemistry, 2018, 02-22, Volume: 61, Issue:4 Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Drug Design; Endoplasmic Reticulum Chaperone BiP; Humans; Mice; Mitochondria; Oxidative Stress; Pancreatic Neoplasms; Quinazolinones; Reactive Oxygen Species; Tumor Cells, Cultured; Unfolded Protein Response; Xenograft Model Antitumor Assays	2018
New somatostatin-drug conjugates for effective targeting pancreatic cancer. Bioorganic & medicinal chemistry, 2018, 07-30, Volume: 26, Issue:13 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Humans; Indoles; Kidney; Pancreatic Neoplasms; Peptides, Cyclic; Receptors, Somatostatin; Somatostatin; Stilbenes; Tissue Distribution; Xenograft Model Antitumor Assays	2018
A single microbubble formulation carrying 5-fluorouridine, Irinotecan and oxaliplatin to enable FOLFIRINOX treatment of pancreatic and colon cancer using ultrasound targeted microbubble destruction. Journal of controlled release : official journal of the Controlled Release Society, 2021, 10-10, Volume: 338 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Mice; Microbubbles; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome; Uridine	2021
All You Need to Know About JCO oncology practice, 2022, Volume: 18, Issue:4 Topics: Camptothecin; Genetic Testing; Glucuronosyltransferase; Humans; Irinotecan; Pancreatic Neoplasms; Polymorphism, Genetic; United States	2022
[A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:13 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Oxaliplatin; Pancreatic Neoplasms	2021
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin. Journal of hepato-biliary-pancreatic sciences, 2022, Volume: 29, Issue:6 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome	2022
Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer. Investigational new drugs, 2022, Volume: 40, Issue:3 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; HEK293 Cells; Humans; Magnetic Iron Oxide Nanoparticles; Nanoparticles; Pancreatic Neoplasms	2022
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. Current medical research and opinion, 2022, Volume: 38, Issue:8 Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; Camptothecin; Diarrhea; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Nausea; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Thrombocytopenia; Vomiting	2022
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2022, Volume: 22, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies	2022
Efficacy and Safety of the Combination of Nano-Liposomal Irinotecan and 5-Fluorouracil/L-Leucovorin in Unresectable Advanced Pancreatic Cancer: A Real-World Study. Oncology, 2022, Volume: 100, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies	2022
Anti-tumor effects and mechanism of a novel camptothecin derivative YCJ100. Life sciences, 2022, Dec-15, Volume: 311, Issue:Pt A Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Topoisomerases, Type I; Female; Humans; Liver Neoplasms; Mice; Molecular Docking Simulation; Pancreatic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays	2022
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer medicine, 2023, Volume: 12, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Rectal Neoplasms	2023
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC). Bulletin du cancer, 2023, Volume: 110, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies	2023
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study. Pancreas, 2022, 09-01, Volume: 51, Issue:8 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms	2022
Biomarker analysis for patients with pancreatic cancer treated with nanoliposomal irinotecan plus 5-fluorouracil/leucovorin. BMC cancer, 2023, Jan-20, Volume: 23, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome	2023
Ultrasound-Triggered Piezocatalysis for Selectively Controlled NO Gas and Chemodrug Release to Enhance Drug Penetration in Pancreatic Cancer. ACS nano, 2023, 02-28, Volume: 17, Issue:4 Topics: Animals; Camptothecin; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Mice; Nanoparticles; Nitric Oxide; Pancreatic Neoplasms; Prodrugs; Tumor Microenvironment	2023
Disulfide Bond-Based SN38 Prodrug Nanoassemblies with High Drug Loading and Reduction-Triggered Drug Release for Pancreatic Cancer Therapy. International journal of nanomedicine, 2023, Volume: 18 Topics: Camptothecin; Cell Line, Tumor; Disulfides; Drug Delivery Systems; Drug Liberation; Humans; Irinotecan; Nanoparticles; Pancreatic Neoplasms; Prodrugs	2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. Cancer medicine, 2023, Volume: 12, Issue:13 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient Care; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Pancreatic Neoplasms	2023
Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer. BMC cancer, 2023, Jul-31, Volume: 23, Issue:1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Liposomes; Male; Pancreatic Neoplasms; Retrospective Studies	2023
Comparison of conventional versus liposomal irinotecan in combination with fluorouracil for advanced pancreatic cancer: a single-institution experience. Medical oncology (Northwood, London, England), 2019, Sep-07, Volume: 36, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies	2019
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:3 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure	2020
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. American journal of clinical oncology, 2019, Volume: 42, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome	2019
Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells. Nanoscale, 2020, Jun-04, Volume: 12, Issue:21 Topics: Antibodies; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Cetuximab; Drug Delivery Systems; ErbB Receptors; Humans; Immunoglobulin Fab Fragments; Nanoparticles; Pancreatic Neoplasms; Surface Properties	2020
[Nanoliposomal Irinotecan in Combination with Fluorouracil and Folinic Acid, As a New Option for Second-Line Treatment in Metastatic Pancreatic Cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Europe; Fluorouracil; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Pancreatic Neoplasms; Quality of Life	2020
FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. The oncologist, 2020, Volume: 25, Issue:11 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Retrospective Studies	2020
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out? ESMO open, 2020, Volume: 5, Issue:5 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2020
Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer treatment and research communications, 2021, Volume: 27 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Mutation; Neoplasm Staging; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Treatment Outcome	2021
Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. European journal of drug metabolism and pharmacokinetics, 2021, Volume: 46, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carboxylesterase; Cytochrome P-450 CYP3A; Fluorouracil; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Models, Biological; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic	2021
Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: Using cumulative relative dose intensity. European journal of cancer (Oxford, England : 1990), 2017, Volume: 76 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy-Induced Febrile Neutropenia; Dose-Response Relationship, Drug; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2017
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Journal of the National Cancer Institute, 2017, 10-01, Volume: 109, Issue:10 Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate	2017
Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget, 2017, Jul-04, Volume: 8, Issue:27 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Piperazines; Retreatment; Treatment Outcome	2017
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer. The oncologist, 2017, Volume: 22, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States	2017
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. Annals of surgical oncology, 2017, Volume: 24, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate	2017
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer. Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:12 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia	2017
Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. Cancer letters, 2017, 10-10, Volume: 406 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate	2017
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. Expert review of clinical pharmacology, 2017, Volume: 10, Issue:10 Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors	2017
Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials, 2017, Volume: 144 Topics: Anilides; Animals; Antineoplastic Agents; Camptothecin; Coculture Techniques; Drug Resistance, Neoplasm; Drug Synergism; Female; Fibroblasts; Hedgehog Proteins; Humans; Irinotecan; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Pyridines; Rats, Sprague-Dawley; Signal Transduction	2017
A Pancreatic Predicament. International journal of radiation oncology, biology, physics, 2017, 10-01, Volume: 99, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery; Tomography, X-Ray Computed; Tumor Burden	2017
Appendix 6: Cancer of the pancreas: MCBS eUpdate published online 20 June 2017 (www.esmo.org/Guidelines/Gastrointestinal-Cancers). Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Jul-01, Volume: 28, Issue:suppl_4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Medical Oncology; Nanostructures; Neoplasm Metastasis; Pancreatic Neoplasms	2017
Photodynamic Priming Mitigates Chemotherapeutic Selection Pressures and Improves Drug Delivery. Cancer research, 2018, 01-15, Volume: 78, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Camptothecin; Cell Proliferation; Drug Delivery Systems; Humans; Irinotecan; Liposomes; Male; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Photochemotherapy; Receptors, CXCR4; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018
MTOR inhibitor-based combination therapies for pancreatic cancer. British journal of cancer, 2018, 02-06, Volume: 118, Issue:3 Topics: Animals; Antineoplastic Agents; Benzoxazoles; Bortezomib; Camptothecin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyrimidines; TOR Serine-Threonine Kinases	2018
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues]. Bulletin du cancer, 2018, Volume: 105, Issue:9 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic	2018
FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. Journal of surgical oncology, 2018, Volume: 118, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Chemoradiotherapy; Cohort Studies; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate	2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancer. Journal for immunotherapy of cancer, 2018, 11-20, Volume: 6, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Camptothecin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Fluorouracil; Humans; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Oxaliplatin; Pancreatic Neoplasms	2018
[FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 6 and or UGT1A128 Polymorphisms-A Report of Two Cases]. Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Polymorphism, Genetic	2019
Chain-Length- and Saturation-Tuned Mechanics of Fluid Nanovesicles Direct Tumor Delivery. ACS nano, 2019, 07-23, Volume: 13, Issue:7 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Screening Assays, Antitumor; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Molecular; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Pancreatic Neoplasms; Particle Size; Stress, Mechanical; Surface Properties; Tumor Cells, Cultured	2019
Advancements in the management of pancreatic cancer: 2013. JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Models, Biological; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms	2013
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy. Onkologie, 2013, Volume: 36, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Remission Induction; Treatment Outcome	2013
FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. The oncologist, 2013, Volume: 18, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2013
Multifocal anaplastic pancreatic carcinoma requiring neoadjuvant chemotherapy and total pancreatectomy: report of a case. JOP : Journal of the pancreas, 2013, May-10, Volume: 14, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome	2013
FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future? The oncologist, 2013, Volume: 18, Issue:5 Topics: Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2013
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs. Journal of biotechnology, 2013, Jul-20, Volume: 166, Issue:4 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camptothecin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Tissue Scaffolds; Xenograft Model Antitumor Assays	2013
Treatment of borderline resectable pancreatic cancer. Current treatment options in oncology, 2013, Volume: 14, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome	2013
Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery. International journal of nanomedicine, 2013, Volume: 8 Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Survival; Drug Delivery Systems; Flow Cytometry; Fluorouracil; Humans; Irinotecan; Leucovorin; Nanofibers; Nanotechnology; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tumor Cells, Cultured	2013
FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience. Anti-cancer drugs, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Carcinoma; Cohort Studies; Drug Monitoring; Female; Fluorouracil; Gallbladder Neoplasms; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Secondary Prevention; Severity of Illness Index; Survival Analysis	2013
Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. Journal of surgical oncology, 2013, Volume: 108, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Treatment Outcome	2013
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Dysarthria; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Recurrence; Time Factors	2014
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma. Pancreas, 2013, Volume: 42, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Filgrastim; Fluorouracil; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Treatment Outcome	2013
Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro. Radiation oncology (London, England), 2013, Nov-06, Volume: 8 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carbon; Cell Cycle; Cell Line, Tumor; Cell Separation; Chemoradiotherapy; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Glioblastoma; Humans; Ions; Lung Neoplasms; Paclitaxel; Pancreatic Neoplasms; Photons; Propidium; Radiotherapy; Relative Biological Effectiveness; Time Factors	2013
[A case of recurrent pancreatic cancer effectively responding to S-1 combined irinotecan third-line chemotherapy with PSK]. Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:10 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Oxonic Acid; Pancreatic Neoplasms; Proteoglycans; Recurrence; Salvage Therapy; Tegafur	2013
Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. International journal of oncology, 2014, Volume: 44, Issue:1 Topics: Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sex Characteristics; Treatment Outcome	2014
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma. Onkologie, 2013, Volume: 36, Issue:12 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome	2013
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. JOP : Journal of the pancreas, 2014, Jan-10, Volume: 15, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cholangitis; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Sepsis	2014
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy. Chemotherapy, 2013, Volume: 59, Issue:4 Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult	2013
FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report. Zeitschrift fur Gastroenterologie, 2014, Volume: 52, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2014
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. Clinics and research in hepatology and gastroenterology, 2014, Volume: 38, Issue:2 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure	2014
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? The oncologist, 2014, Volume: 19, Issue:3 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2014
FOLFIRINOX: from the ACCORD study to 2014. JOP : Journal of the pancreas, 2014, Mar-10, Volume: 15, Issue:2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Fluorouracil; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome	2014
Updates on first-line therapy for metastatic pancreatic adenocarcinoma. JOP : Journal of the pancreas, 2014, Mar-10, Volume: 15, Issue:2 Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome	2014
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. BMJ case reports, 2014, Apr-03, Volume: 2014 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Induced Febrile Neutropenia; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Sepsis	2014
Caring for one of our own. The oncologist, 2014, Volume: 19, Issue:5 Topics: Camptothecin; Caregivers; Diphosphonates; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nurses; Organoplatinum Compounds; Oxaliplatin; Pain; Pain Management; Pancreatic Neoplasms; Patient-Centered Care; Physician-Patient Relations	2014
Danish experiences with FOLFIRINOX as first-line therapy in patients with inoperable pancreatic cancer. Danish medical journal, 2014, Volume: 61, Issue:4 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Denmark; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vitamin B Complex	2014
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea. Pancreas, 2014, Volume: 43, Issue:7 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome	2014
A R0 resection case of initially unresectable metastatic pancreatic cancer downstaged by FOLFIRINOX therapy. Pancreas, 2014, Volume: 43, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome	2014
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Annals of surgical oncology, 2015, Volume: 22, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate	2015
Locally advanced unresectable pancreatic cancer. JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome	2014
Establishment of an orthotopic model of pancreatic cancer to evaluate the antitumor effects of irinotecan through the biomarker carbohydrate antigen 19-9 in mice. Pancreas, 2014, Volume: 43, Issue:7 Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays	2014
Complete radiological response of an initially locally advanced unresectable pancreatic cancer to chemoradiotherapy using FOLFIRINOX regimen: report of a case. Clinics and research in hepatology and gastroenterology, 2015, Volume: 39, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2015
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Annals of surgical oncology, 2015, Volume: 22, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate	2015
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort. Scandinavian journal of gastroenterology, 2014, Volume: 49, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome	2014
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Clinical colorectal cancer, 2014, Volume: 13, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate	2014
A bioengineered murine model using CD24⁺CD44⁺ pancreatic cancer stem cells for chemotherapy study. Biomedical materials (Bristol, England), 2014, Dec-23, Volume: 10, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; Biomedical Engineering; Camptothecin; CD24 Antigen; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Tissue Scaffolds	2014
Neoadjuvant therapy for localized pancreatic cancer: support is growing? Annals of surgery, 2015, Volume: 261, Issue:1 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2015
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Annals of surgery, 2015, Volume: 261, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Disease-Free Survival; Female; Fluorouracil; Humans; Imaging, Three-Dimensional; Irinotecan; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Spiral Cone-Beam Computed Tomography; Treatment Outcome	2015
Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. Journal of gastrointestinal cancer, 2015, Volume: 46, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis	2015
[After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2015, Volume: 86, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms	2015
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Oncology, 2015, Volume: 89, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies; Risk Factors; Splenectomy; Treatment Outcome	2015
[FOLFIRINOX, nab-paclitaxel + gemcitabine]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73 Suppl 3 Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms	2015
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2. Oncotarget, 2015, May-10, Volume: 6, Issue:13 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Cell Line, Tumor; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Irinotecan; Male; Membrane Transport Proteins; Mice, SCID; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Receptor, ErbB-2; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Xenograft Model Antitumor Assays	2015
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. Clinical therapeutics, 2015, Jun-01, Volume: 37, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom	2015
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjugate chemistry, 2015, May-20, Volume: 26, Issue:5 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Apoptosis; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Clinical Trials as Topic; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Irinotecan; Mice; Pancreatic Neoplasms; Signal Transduction; Stomach Neoplasms; Xenograft Model Antitumor Assays	2015
Predicting a response to FOLFIRINOX in pancreatic cancer. Journal of the National Cancer Institute, 2015, Volume: 107, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboxylesterase; Carcinoma, Pancreatic Ductal; Female; Humans; Male; Pancreatic Neoplasms	2015
Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma. Journal of the National Cancer Institute, 2015, Volume: 107, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboxylesterase; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Mass Spectrometry; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sequence Analysis, RNA; Tissue Array Analysis; Treatment Outcome; Xenograft Model Antitumor Assays	2015
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection. World journal of gastroenterology, 2015, May-28, Volume: 21, Issue:20 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden	2015
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability. Journal of surgical oncology, 2015, Volume: 111, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis	2015
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, Nov-15, Volume: 21, Issue:22 Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Humans; Immunoconjugates; Irinotecan; Mice; Pancreatic Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays	2015
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocrine-related cancer, 2015, Volume: 22, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Ki-67 Antigen; Leucovorin; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult	2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2016
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. American journal of clinical oncology, 2017, Volume: 40, Issue:6 Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Camptothecin; Eligibility Determination; Female; Fluorouracil; Humans; Hyperbilirubinemia; Irinotecan; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Renal Insufficiency; Retrospective Studies	2017
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience. Hepato-gastroenterology, 2014, Volume: 61, Issue:131 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome	2014
Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II. Journal of drug targeting, 2016, Volume: 24, Issue:2 Topics: Animals; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Mice; Mice, Nude; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides; Receptors, Notch; Receptors, Peptide; Receptors, Somatostatin; Repressor Proteins; Signal Transduction; Valproic Acid	2016
Relationship between UGT1A16/28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug design, development and therapy, 2015, Volume: 9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Camptothecin; Female; Fluorouracil; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Genetic; Retrospective Studies; Severity of Illness Index; Young Adult	2015
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. Journal of gastroenterology and hepatology, 2016, Volume: 31, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome	2016
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. Annals of surgical oncology, 2015, Volume: 22 Suppl 3 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate	2015
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:14 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pakistan; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate	2015
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Annals of surgical oncology, 2015, Volume: 22 Suppl 3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate	2015
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. Oncology, 2015, Volume: 89, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies	2015
Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer. Cancer research, 2016, Mar-01, Volume: 76, Issue:5 Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Stability; Humans; Inhibitor of Apoptosis Proteins; Irinotecan; Liposomes; Male; Mice; Monocarboxylic Acid Transporters; Muscle Proteins; Nanoparticles; Neoplasm Proteins; Pancreatic Neoplasms; Photochemotherapy; Porphyrins; Survivin; Treatment Outcome	2016
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate	2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium	2015
Irinotecan Delivery by Lipid-Coated Mesoporous Silica Nanoparticles Shows Improved Efficacy and Safety over Liposomes for Pancreatic Cancer. ACS nano, 2016, Feb-23, Volume: 10, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Drug Liberation; Female; Irinotecan; Lipid Bilayers; Liposomes; Mice; Nanoparticles; Pancreatic Neoplasms; Silicon Dioxide	2016
Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, Feb-23, Volume: 113, Issue:8 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Cell Proliferation; Fluorouracil; Humans; Infusion Pumps, Implantable; Iontophoresis; Leucovorin; Mice; Mice, Nude; Organoplatinum Compounds; Pancreatic Neoplasms; Xenograft Model Antitumor Assays	2016
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11. Oncotarget, 2016, Mar-29, Volume: 7, Issue:13 Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Deoxycytidine; DNA Damage; Down-Regulation; Gemcitabine; Genes, Viral; Humans; Irinotecan; MRE11 Homologue Protein; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms	2016
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20 Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Female; Histones; Humans; Immunoconjugates; Macaca fascicularis; Maytansine; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Receptor, ErbB-2; Topoisomerase I Inhibitors; Trastuzumab	2016
[Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2016, Apr-01, Volume: 54, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tertiary Care Centers; Treatment Outcome	2016
First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. International journal of cancer, 2016, Aug-15, Volume: 139, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Female; Fluorouracil; Humans; Leucovorin; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neutrophils; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome	2016
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials. Tumori, 2016, Jun-02, Volume: 2016, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis	2016
Effectiveness and Tolerability of Maintenance Capecitabine Administrated to Patients with Metastatic Pancreatic Cancer Treated with First-Line FOLFIRINOX. Oncology, 2016, Volume: 90, Issue:5 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2016
ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. Oncotarget, 2016, Jun-07, Volume: 7, Issue:23 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Treatment Outcome	2016
In brief: liposomal irinotecan (Onivyde) for pancreatic cancer. The Medical letter on drugs and therapeutics, 2016, Jun-06, Volume: 58, Issue:1496 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Compounding; Fluorouracil; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Treatment Outcome	2016
Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24 Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Heterografts; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Retrospective Studies; Xenograft Model Antitumor Assays	2016
Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? Journal of surgical oncology, 2016, Volume: 114, Issue:5 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Fluorouracil; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Preoperative Care; Retrospective Studies; Treatment Outcome	2016
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience. British journal of cancer, 2016, 09-06, Volume: 115, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome	2016
Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma. Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Pancreatic Ductal; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Prognosis; Rare Diseases; Retrospective Studies; Survival Analysis	2016
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital. Zeitschrift fur Gastroenterologie, 2016, Volume: 54, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate	2016
Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models. Oncotarget, 2017, Jan-17, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; DNA Damage; Humans; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Resorcinols; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2017
Sphingomyelin Liposomes Containing Porphyrin-phospholipid for Irinotecan Chemophototherapy. Theranostics, 2016, Volume: 6, Issue:13 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Models, Animal; Drug Carriers; Heterografts; Infrared Rays; Irinotecan; Liposomes; Mice; Pancreatic Neoplasms; Phospholipids; Porphyrins; Sphingomyelins; Treatment Outcome	2016
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. European radiology, 2017, Volume: 27, Issue:7 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex	2017
Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, 02-20, Volume: 35, Issue:6 Topics: Camptothecin; Humans; Irinotecan; Medical Oncology; Pancreatic Neoplasms; United States	2017
Granulocyte Colony-stimulating Factor Producing Anaplastic Carcinoma of the Pancreas: Case Report and Review of the Literature. Anticancer research, 2017, Volume: 37, Issue:1 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leukocyte Count; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Receptors, Granulocyte Colony-Stimulating Factor; Tomography Scanners, X-Ray Computed	2017
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study. Digestion, 2016, Volume: 94, Issue:4 Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires	2016
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis. Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:2 Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome	2017
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX. Expert review of clinical pharmacology, 2017, Volume: 10, Issue:5 Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Delivery of Health Care; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Time Factors	2017
Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas. Pancreas, 2017, Volume: 46, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Acinar Cell; Carcinoma, Islet Cell; Combined Modality Therapy; Fluorouracil; Humans; Irinotecan; Laparotomy; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Period; Treatment Outcome	2017
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC cancer, 2008, Jul-08, Volume: 8 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2008
Metronomic chemotherapy and tumor immunomodulation. Cancer biology & therapy, 2008, Volume: 7, Issue:4 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Mice; Mice, Nude; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays	2008
Bruceine D induces apoptosis in pancreatic adenocarcinoma cell line PANC-1 through the activation of p38-mitogen activated protein kinase. Cancer letters, 2009, Aug-18, Volume: 281, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Cell Division; Cell Line, Tumor; DNA Replication; Enzyme Activation; Fibroblasts; Humans; Neoplasm Proteins; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Quassins	2009
Experimental study of combination therapy with S-1 against pancreatic cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays	2009
[A case of recurrent endocrine cell carcinoma of the common bile duct successfully treated by hepatic artery infusion with CPT-11 and CDDP]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Camptothecin; Cisplatin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Tomography, X-Ray Computed	2009
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. JOP : Journal of the pancreas, 2009, Jul-06, Volume: 10, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome	2009
CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Oct-01, Volume: 15, Issue:19 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoembryonic Antigen; Carcinoma; Colonic Neoplasms; Drug Delivery Systems; Female; GPI-Linked Proteins; Humans; Immunoconjugates; Irinotecan; Mice; Mice, Nude; Models, Biological; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2009
[A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:11 Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms	2009
Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour. European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:3 Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Drug Delivery Systems; Enzyme Inhibitors; Female; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Pancreatic Neoplasms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays	2010
En bloc resection for right colon cancer directly invading duodenum or pancreatic head. Yonsei medical journal, 2009, Dec-31, Volume: 50, Issue:6 Topics: Adult; Aged; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Duodenal Neoplasms; Duodenum; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome	2009
Nuclear factor (erythroid-derived 2)-like 2 regulates drug resistance in pancreatic cancer cells. Pancreas, 2010, Volume: 39, Issue:4 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Survival; Cisplatin; Cytoplasm; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Neoplasm Proteins; NF-E2-Related Factor 2; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference	2010
Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. American journal of clinical oncology, 2010, Volume: 33, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis	2010
Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer. Journal of materials science. Materials in medicine, 2010, Volume: 21, Issue:9 Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Humans; Irinotecan; Pancreatic Neoplasms; Topotecan	2010
Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report. World journal of gastroenterology, 2010, Aug-14, Volume: 16, Issue:30 Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Administration Schedule; Endocrine Gland Neoplasms; Etoposide; Gemcitabine; Humans; Ileus; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Failure	2010
Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit. JOP : Journal of the pancreas, 2010, Nov-09, Volume: 11, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pain; Palliative Care; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome	2010
Application of human pancreatic carcinoid BON cells for receptor-targeted drug development. Journal of drug targeting, 2011, Volume: 19, Issue:8 Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bibenzyls; Bombesin; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Design; Humans; Ligands; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Binding; Real-Time Polymerase Chain Reaction; Receptors, Bombesin; Receptors, Cell Surface; Receptors, Somatostatin; Somatostatin; Xenograft Model Antitumor Assays	2011
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer research, 2010, Volume: 30, Issue:11 Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult	2010
In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells. The American journal of Chinese medicine, 2011, Volume: 39, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Caspase 3; Caspase 9; Cell Line, Tumor; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; NF-kappa B; Pancreatic Neoplasms; Phenanthrenes; Phytotherapy; Plant Extracts; Signal Transduction; Tripterygium	2011
Paclitaxel-induced apoptosis is blocked by camptothecin in human breast and pancreatic cancer cells. Oncology reports, 2011, Volume: 25, Issue:5 Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Diterpenes, Kaurane; Drug Stability; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucosides; HL-60 Cells; Humans; Paclitaxel; Pancreatic Neoplasms; Solvents	2011
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome	2011
Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011. JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Treatment Outcome	2011
Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. Neoplasia (New York, N.Y.), 2011, Volume: 13, Issue:3 Topics: Adenosine Triphosphatases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Axitinib; Blotting, Western; Camptothecin; Cation Transport Proteins; Cell Proliferation; Cells, Cultured; Copper-Transporting ATPases; Drug Synergism; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; Humans; Imidazoles; Immunoenzyme Techniques; Indazoles; Irinotecan; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thrombospondins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2011
Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Molecular cancer therapeutics, 2011, Volume: 10, Issue:6 Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Camptothecin; Cell Line, Tumor; Female; Humans; Immunotoxins; Irinotecan; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2011
Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging. Molecular imaging, 2011, Volume: 10, Issue:3 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cell Line, Tumor; Cetuximab; Contrast Media; Humans; Irinotecan; Magnetic Resonance Imaging; Mice; Mice, SCID; Pancreatic Neoplasms; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Tumor Burden; Xenograft Model Antitumor Assays	2011
In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine : nanotechnology, biology, and medicine, 2012, Volume: 8, Issue:2 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Folic Acid; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Pancreatic Neoplasms; Silicates; Transplantation, Heterologous	2012
Chemotherapy: Metastatic pancreatic cancer--is FOLFIRINOX the new standard? Nature reviews. Clinical oncology, 2011, Jul-05, Volume: 8, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2011
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Journal of the National Cancer Institute, 2011, Aug-03, Volume: 103, Issue:15 Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Silencing; Humans; Irinotecan; MAP Kinase Kinase Kinases; Mice; Mice, Nude; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays	2011
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology, 2011, Volume: 80, Issue:5-6 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome	2011
Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. Molecular cancer therapeutics, 2011, Volume: 10, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Camptothecin; Cell Line, Tumor; Female; HT29 Cells; Humans; Immunohistochemistry; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Shiga Toxins; Topoisomerase I Inhibitors	2011
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011, Aug-01, Volume: 25, Issue:4 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2011
Pancreatic β-cell death in response to pro-inflammatory cytokines is distinct from genuine apoptosis. PloS one, 2011, Volume: 6, Issue:7 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Cell Death; Cells, Cultured; Cytokines; Enzyme Inhibitors; Inflammation; Insulin; Insulin-Secreting Cells; Insulinoma; Interferon-gamma; Interleukin-1beta; Metabolomics; NF-kappa B; Pancreatic Neoplasms; Rats; Signal Transduction; Staurosporine; Tandem Mass Spectrometry	2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine, 2011, 08-25, Volume: 365, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2011
FOLFIRINOX: a small step or a great leap forward? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Oct-01, Volume: 29, Issue:28 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2011
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts. Oncology reports, 2012, Volume: 27, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays	2012
A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model. Small (Weinheim an der Bergstrasse, Germany), 2012, Mar-26, Volume: 8, Issue:6 Topics: Animals; Camptothecin; Dextrans; Disease Models, Animal; Irinotecan; Mice; Pancreatic Neoplasms; Prodrugs; Rabbits	2012
Development of a combination drug-eluting bead: towards enhanced efficacy for locoregional tumour therapies. Anti-cancer drugs, 2012, Volume: 23, Issue:4 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Doxorubicin; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Prostheses and Implants; Sirolimus; Topotecan; Xenograft Model Antitumor Assays	2012
Noxa/Mcl-1 balance influences the effect of the proteasome inhibitor MG-132 in combination with anticancer agents in pancreatic cancer cell lines. Anti-cancer drugs, 2012, Volume: 23, Issue:6 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Cell Line, Tumor; Doxorubicin; Humans; Leupeptins; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2	2012
Abietane diterpenes induce cytotoxic effects in human pancreatic cancer cell line MIA PaCa-2 through different modes of action. Phytochemistry, 2012, Volume: 78 Topics: Abietanes; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Cycle; Diterpenes; Drug Screening Assays, Antitumor; Humans; Pancreatic Neoplasms; Plants, Medicinal; Pyridines; Topoisomerase I Inhibitors	2012
Conventional chemotherapy of advanced pancreatic cancer. Current drug targets, 2012, Volume: 13, Issue:6 Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2012
Involvement of the mitochondrial pathway in bruceine D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma cells. International journal of molecular medicine, 2012, Volume: 30, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Brucea; Camptothecin; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; Drugs, Chinese Herbal; Gemcitabine; Hepatocytes; Humans; Membrane Potential, Mitochondrial; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quassins; Stem Cells	2012
Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways. Toxicology and applied pharmacology, 2012, Jul-01, Volume: 262, Issue:1 Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Cell Line; Cell Line, Tumor; Diterpenes; G2 Phase Cell Cycle Checkpoints; Humans; Liver; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2012
[Two cases of CPT-11 and CDDP chemotherapy for advanced pancreatic cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:5 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Tomography, X-Ray Computed	2012
A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC cancer, 2012, May-29, Volume: 12 Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome	2012
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning. Pancreas, 2012, Volume: 41, Issue:6 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Fluorouracil; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome	2012
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocrine-related cancer, 2012, Volume: 19, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Camptothecin; Carcinoma, Neuroendocrine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Pelvic Neoplasms; Platinum; Treatment Outcome	2012
Mitogen-activated protein kinase (MEK/ERK) inhibition sensitizes cancer cells to centromere-associated protein E inhibition. International journal of cancer, 2013, Feb-01, Volume: 132, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Benzamides; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; Colonic Neoplasms; Dacarbazine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Irinotecan; Lung Neoplasms; M Phase Cell Cycle Checkpoints; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Neuroblastoma; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Sarcosine; Temozolomide	2013
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. World journal of gastroenterology, 2012, Sep-07, Volume: 18, Issue:33 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome	2012
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. Anticancer research, 2012, Volume: 32, Issue:9 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome	2012
Progress in pancreatic cancer: moving beyond gemcitabine? Expert review of anticancer therapy, 2012, Volume: 12, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2012
Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer science, 2013, Volume: 104, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Collagen; Female; Humans; Immunoconjugates; Irinotecan; Lymphoma; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Topoisomerase I Inhibitors	2013
Double pancreatic and gastric adenocarcinomas: a rare association. Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:6 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rare Diseases; Stomach Neoplasms; Tomography, X-Ray Computed	2013
Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Humans; Irinotecan; Leucovorin; Male; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms	2013
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma. Pancreas, 2013, Volume: 42, Issue:1 Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillus fumigatus; Camptothecin; Fluorouracil; Humans; Invasive Pulmonary Aspergillosis; Irinotecan; Male; Middle Aged; Neutropenia; Opportunistic Infections; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pneumocystis carinii; Pneumonia, Pneumocystis; Tomography, X-Ray Computed; Treatment Outcome	2013
Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis. Cancer gene therapy, 2013, Volume: 20, Issue:2 Topics: Camptothecin; Cell Line, Tumor; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Herpesvirus 1, Human; Humans; Irinotecan; Methotrexate; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Transcriptional Activation; Tumor Necrosis Factor-alpha; Virus Replication	2013
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen. British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome	2002
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer research, 2003, Jan-01, Volume: 63, Issue:1 Topics: Animals; Camptothecin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured	2003
A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics. The Journal of surgical research, 2003, Volume: 113, Issue:1 Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Luminescent Proteins; Male; Mice; Mice, Nude; Models, Animal; Neoplasm Metastasis; Pancreatic Neoplasms; Predictive Value of Tests; Red Fluorescent Protein; Transduction, Genetic; Tumor Cells, Cultured	2003
Two new drugs for colon cancer. The Medical letter on drugs and therapeutics, 2004, Jun-07, Volume: 46, Issue:1184 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colonic Neoplasms; Colorectal Neoplasms; Humans; Irinotecan; Lung Neoplasms; Pancreatic Neoplasms	2004
[A case report of metastatic pancreatic cancer that responded remarkably to the combination of thalidomide, celecoxib and irinotecan]. Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase 2; Drug Administration Schedule; Female; Humans; Irinotecan; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Sulfonamides; Thalidomide; Tumor Necrosis Factor-alpha	2004
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer]. Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate	2004
Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods in molecular medicine, 2005, Volume: 111 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Cytosine; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Fluorouracil; Green Fluorescent Proteins; Humans; Immunotherapy; Interferons; Liposomes; Liver; Liver Neoplasms; Luminescent Proteins; Lung Neoplasms; Male; Metalloproteases; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Neoplasms, Experimental; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Red Fluorescent Protein	2005
Current and future strategies for treating metastatic pancreatic cancer. Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:8 Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Management; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome	2004
[A case of small cell carcinoma of the stomach]. Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Rupture, Spontaneous; Stomach Neoplasms; Stomach Rupture	2005
Are there any better camptothecins than the ones we have? Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:10 Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors	2003
Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5 Topics: Animals; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Colorectal Neoplasms; Cyclodextrins; Disease Models, Animal; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Nanotechnology; Pancreatic Neoplasms; Polymers; Sarcoma, Ewing; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2006
Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Archiv : an international journal of pathology, 2006, Volume: 448, Issue:6 Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Irinotecan; Pancreatic Neoplasms; Protein Synthesis Inhibitors	2006
[Long-term repeatable chemotherapy for patients with advanced pancreatic cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33 Suppl 1 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Tegafur	2006
Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain. Cancer biology & therapy, 2006, Volume: 5, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Bile Ducts; Biliary Tract; Camptothecin; Drainage; Feces; Humans; Irinotecan; Liver; Liver Neoplasms; Male; Pancreatic Neoplasms; Prodrugs	2006
Exatecan and gemcitabine: no better than gemcitabine only. The Lancet. Oncology, 2006, Volume: 7, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate	2006
Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells. Cancer research, 2006, Dec-01, Volume: 66, Issue:23 Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Injections, Intravenous; Irinotecan; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microspheres; Neoplasm Transplantation; Pancreatic Neoplasms; Portal Vein; Rats; Rats, Nude; Transplantation, Heterologous	2006
[In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2006, Volume: 28, Issue:6 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Cell Survival; Colorectal Neoplasms; Docetaxel; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured	2006
[Successful CPT-11 treatment in a patient with pancreatic cancer associated with multiple liver metastases and chronic renal failure]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:1 Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Irinotecan; Kidney Failure, Chronic; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Remission Induction	2007
A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer. British journal of cancer, 2007, May-07, Volume: 96, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Female; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, Nude; Pancreatic Neoplasms; Pemetrexed; Transplantation, Heterologous	2007
Cationic lipid complexed camptothecin (EndoTAG-2) improves antitumoral efficacy by tumor vascular targeting. Cancer biology & therapy, 2007, Volume: 6, Issue:6 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cations; Cell Line, Tumor; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Microscopy, Fluorescence; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms	2007
[A case of unresectable advanced pancreatic cancer treated by S-1 with concurrent radiotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6 Topics: Adenocarcinoma; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Camptothecin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Tegafur	2007
Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Sep-15, Volume: 13, Issue:18 Pt 2 Topics: Adenosine Triphosphate; Animals; Annexin A5; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Combined Modality Therapy; Female; Humans; Irinotecan; Membrane Potential, Mitochondrial; Mice; Mice, SCID; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Survival Rate; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays	2007
Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Mar-15, Volume: 14, Issue:6 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mice; Mice, Nude; Models, Biological; Neoplasms; Pancreatic Neoplasms; Polyethylene Glycols; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2008
Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer biology & therapy, 2008, Volume: 7, Issue:4 Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Topotecan; Xenograft Model Antitumor Assays	2008
Enhanced distribution of NK012, a polymeric micelle-encapsulated SN-38, and sustained release of SN-38 within tumors can beat a hypovascular tumor. Cancer science, 2008, Volume: 99, Issue:6 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Chromatography, High Pressure Liquid; Collagen Type I; Delayed-Action Preparations; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Fluorescence; Pancreatic Neoplasms; Prodrugs; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2008
[Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)]. Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms	1994
The use of 7-amino actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood, 1996, Mar-15, Volume: 87, Issue:6 Topics: Apoptosis; Camptothecin; Carcinoma; Cell Count; Cell Separation; Dactinomycin; DNA Damage; DNA, Neoplasm; Flow Cytometry; Fluorescent Dyes; Humans; Leukemia-Lymphoma, Adult T-Cell; Leukemia, Erythroblastic, Acute; Pancreatic Neoplasms; Reproducibility of Results; Sensitivity and Specificity; Tumor Cells, Cultured	1996
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Japanese journal of cancer research : Gann, 1997, Volume: 88, Issue:8 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured	1997
[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis]. Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:11 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms	1998
Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer research, 2000, Jan-01, Volume: 60, Issue:1 Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Drug Therapy, Combination; Humans; In Situ Nick-End Labeling; Injections, Intralesional; Irinotecan; Lipopeptides; Lipoproteins; Liver Neoplasms; Lymph Nodes; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Pancreatic Neoplasms; Proliferating Cell Nuclear Antigen; Transplantation, Heterologous; Tumor Cells, Cultured	2000
[Weekly chemotherapy with alternating low-dose CPT-11 and low-dose FP against a far advanced pancreatic cancer--a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:10 Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Male; Pancreatic Neoplasms	2000
Combined radiation and 9-nitrocamptothecin (rubitecan) in the treatment of locally advanced pancreatic cancer. Annals of the New York Academy of Sciences, 2000, Volume: 922 Topics: Animals; Antineoplastic Agents; Camptothecin; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Xenograft Model Antitumor Assays	2000
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. The oncologist, 2001, Volume: 6, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis	2001
Modulation of marrow proliferation and chemosensitivity by tumor-produced cytokines from syngeneic pancreatic tumor lines. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:5 Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Camptothecin; Cell Division; Cell Survival; Culture Media, Conditioned; Cyclophosphamide; Cytokines; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Inhibitory Concentration 50; Interleukin-1; Interleukin-3; Interleukin-6; Irinotecan; Membrane Proteins; Mice; Mice, Inbred Strains; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Isogeneic; Tumor Cells, Cultured	2002
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts. International journal of oncology, 2002, Volume: 21, Issue:1 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Camptothecin; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotides; Oligonucleotides, Antisense; Pancreatic Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome	2002
Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay. Biochemical and biophysical research communications, 1992, Apr-30, Volume: 184, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Blotting, Northern; Camptothecin; Cell Division; Cell Line; DNA Topoisomerases, Type I; Drug Resistance; Gene Expression; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Molecular Sequence Data; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Polymerase Chain Reaction; RNA, Messenger	1992
Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11. Biochemical and biophysical research communications, 1992, Oct-15, Volume: 188, Issue:1 Topics: Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Cell Division; DNA Replication; DNA Topoisomerases, Type I; Drug Resistance; Humans; Irinotecan; Pancreatic Neoplasms; Thymidine; Tumor Cells, Cultured	1992
[Conversion of CPT-11 into SN-38 in human tissues]. Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:12 Topics: Animals; Camptothecin; Chromatography, High Pressure Liquid; Humans; Irinotecan; Liver; Lung; Pancreatic Neoplasms; Rats	1991
[Inhibitory effects of CPT-11 on liver metastases in nude mice injected with human pancreatic tumor cells into their spleens]. Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:12 Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Depression, Chemical; Drug Screening Assays, Antitumor; Female; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Spleen; Tumor Cells, Cultured	1990